M Flint Beal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12014593/publications.pdf

Version: 2024-02-01

458 papers	79,439 citations	231 145 h-index	515 267 g-index
513 all docs	513 docs citations	513 times ranked	53270 citing authors

#	Article	IF	Citations
1	Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 2006, 443, 787-795.	13.7	5,213
2	Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine. Journal of Neuroscience, 2000, 20, 1-7.	1.7	2,029
3	Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinsonâ€™s disease. Nature, 2011, 480, 547-551.	13.7	1,603
4	Aging, energy, and oxidative stress in neurodegenerative diseases. Annals of Neurology, 1995, 38, 357-366.	2.8	1,323
5	Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature, 1986, 321, 168-171.	13.7	1,236
6	Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nature Genetics, 1996, 13, 43-47.	9.4	1,153
7	Effects of Coenzyme Q10 in Early Parkinson Disease. Archives of Neurology, 2002, 59, 1541.	4.9	994
8	Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Annals of Neurology, 1994, 36, 747-751.	2.8	992
9	Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?. Annals of Neurology, 1992, 31, 119-130.	2.8	964
10	Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nature Genetics, 1992, 2, 324-329.	9.4	862
11	Mitochondria take center stage in aging and neurodegeneration. Annals of Neurology, 2005, 58, 495-505.	2.8	839
12	Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia. Annals of Neurology, 1997, 41, 646-653.	2.8	811
13	Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends in Molecular Medicine, 2008, 14, 45-53.	3.5	799
14	Functional engraftment of human ES cellâ€“derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nature Medicine, 2006, 12, 1259-1268.	15.2	771
15	Oxidatively modified proteins in aging and disease1,2 1Guest Editor: Earl Stadtman 2This article is part of a series of reviews on â€œOxidatively Modified Proteins in Aging and Disease.â€•The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine, 2002, 32, 797-803.	1.3	719
16	Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10793-10798.	3.3	717
17	Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Annals of Neurology, 1993, 34, 609-616.	2.8	713
18	Parkinson's disease. Human Molecular Genetics, 2007, 16, R183-R194.	1.4	691

#	Article	IF	Citations
19	Evidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis. Journal of Neurochemistry, 1997, 69, 2064-2074.	2.1	671
20	Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine, 1999, 5, 347-350.	15.2	669
21	Intraneuronal Alzheimer AÎ²42 Accumulates in Multivesicular Bodies and Is Associated with Synaptic Pathology. American Journal of Pathology, 2002, 161, 1869-1879.	1.9	664
22	Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nature Clinical Practice Neurology, 2008, 4, 600-609.	2.7	643
23	Mitochondrial Â-Ketoglutarate Dehydrogenase Complex Generates Reactive Oxygen Species. Journal of Neuroscience, 2004, 24, 7779-7788.	1.7	626
24	Mitochondrial dysfunction in Parkinson's disease. Journal of Neurochemistry, 2016, 139, 216-231.	2.1	607
25	Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo. Neuron, 2003, 37, 899-909.	3.8	594
26	Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nature Biotechnology, 2003, 21, 1200-1207.	9.4	585
27	Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Annals of Neurology, 1997, 42, 644-654.	2.8	565
28	Mitochondrial Dysfunction in Neurodegenerative Diseases. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 619-630.	1.3	557
29	Superoxide Dismutase Activity, Oxidative Damage, and Mitochondrial Energy Metabolism in Familial and Sporadic Amyotrophic Lateral Sclerosis. Journal of Neurochemistry, 1993, 61, 2322-2325.	2.1	555
30	Experimental models of Parkinson's disease. Nature Reviews Neuroscience, 2001, 2, 325-332.	4.9	533
31	Mutated Human SOD1 Causes Dysfunction of Oxidative Phosphorylation in Mitochondria of Transgenic Mice. Journal of Biological Chemistry, 2002, 277, 29626-29633.	1.6	522
32	Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease. Journal of Neuroscience, 2000, 20, 4389-4397.	1.7	502
33	Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10726-10731.	3.3	500
34	Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7070-7075.	3.3	485
35	Reduced-Median-Network Analysis of Complete Mitochondrial DNA Coding-Region Sequences for the Major African, Asian, and European Haplogroups. American Journal of Human Genetics, 2002, 70, 1152-1171.	2.6	482
36	Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nature Neuroscience, 2009, 12, 826-828.	7.1	475

#	Article	IF	Citations
37	Stimulation of Î²-Amyloid Precursor Protein Trafficking by Insulin Reduces Intraneuronal Î²-Amyloid and Requires Mitogen-Activated Protein Kinase Signaling. Journal of Neuroscience, 2001, 21, 2561-2570.	1.7	460
38	Cortical Cytochrome Oxidase Activity Is Reduced in Alzheimer's Disease. Journal of Neurochemistry, 1994, 63, 2179-2184.	2.1	443
39	Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nature Reviews Drug Discovery, 2020, 19, 609-633.	21.5	441
40	Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 120-131.	1.8	439
41	Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochemistry International, 2009, 54, 111-118.	1.9	438
42	Oxidative Stress in Huntington's Disease. Brain Pathology, 1999, 9, 147-163.	2.1	426
43	Inhibition of neuronal nitric oxide synthase prevents MPTPâ€“induced parkinsonism in baboons. Nature Medicine, 1996, 2, 1017-1021.	15.2	415
44	Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Annals of Neurology, 1997, 41, 160-165.	2.8	415
45	Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. Journal of Experimental Medicine, 2010, 207, 117-128.	4.2	411
46	Lipid peroxidation in aging brain and Alzheimerâ€™s disease1,2 1Guest Editors: Mark A. Smith and George Perry 2This article is part of a series of reviews on â€œCauses and Consequences of Oxidative Stress in Alzheimerâ€™s Disease.â€•The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine, 2002, 33, 620-626.	1.3	406
47	Mitochondria, free radicals, and neurodegeneration. Current Opinion in Neurobiology, 1996, 6, 661-666.	2.0	402
48	Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease. Journal of Biological Chemistry, 2005, 280, 556-563.	1.6	401
49	Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntingtonâ€™s Disease. Journal of Neuroscience, 1998, 18, 156-163.	1.7	400
50	Impaired mitochondrial function in psychiatric disorders. Nature Reviews Neuroscience, 2012, 13, 293-307.	4.9	388
51	Therapeutic Effects of Coenzyme Q₁₀and Remacemide in Transgenic Mouse Models of Huntington's Disease. Journal of Neuroscience, 2002, 22, 1592-1599.	1.7	380
52	Inhibition of Neuronal Nitric Oxide Synthase by 7â€Nitroindazole Protects Against MPTPâ€Induced Neurotoxicity in Mice. Journal of Neurochemistry, 1995, 64, 936-939.	2.1	377
53	Mechanisms of excitotoxicity in neurologic diseases. FASEB Journal, 1992, 6, 3338-3344.	0.2	366
54	Age-Dependent Vulnerability of the Striatum to the Mitochondrial Toxin 3-Nitropropionic Acid. Journal of Neurochemistry, 1993, 60, 356-359.	2.1	365

#	Article	IF	Citations
55	Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain, 2008, 131, 389-396.	3.7	362
56	Mitochondrial Diseases of the Brain. Free Radical Biology and Medicine, 2013, 63, 1-29.	1.3	361
57	Sensitivity to Oxidative Stress in DJ-1-Deficient Dopamine Neurons: An ES- Derived Cell Model of Primary Parkinsonism. PLoS Biology, 2004, 2, e327.	2.6	338
58	Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2. PLoS ONE, 2011, 6, e18568.	1.1	338
59	Huntingtin aggregates may not predict neuronal death in Huntington's disease. Annals of Neurology, 1999, 46, 842-849.	2.8	332
60	Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease. Archives of Neurology, 2009, 66, 1460.	4.9	326
61	Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13670-13675.	3.3	325
62	Mitochondria in Neurodegeneration: Acute Ischemia and Chronic Neurodegenerative Diseases. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 351-369.	2.4	324
63	Neuroprotective strategies involving ROS in Alzheimer disease. Free Radical Biology and Medicine, 2011, 51, 1014-1026.	1.3	321
64	High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Human Molecular Genetics, 2002, 11, 133-145.	1.4	318
65	Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. Journal of Neurochemistry, 2002, 80, 616-625.	2.1	315
66	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	4.5	312
67	Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease. Journal of Neuroscience, 2002, 22, 8942-8950.	1.7	307
68	Kynurenine Pathway Measurements in Huntington's Disease Striatum: Evidence for Reduced Formation of Kynurenic Acid. Journal of Neurochemistry, 1990, 55, 1327-1339.	2.1	297
69	Involvement of Free Radicals in Excitotoxicity In Vivo. Journal of Neurochemistry, 1995, 64, 2239-2247.	2.1	290
70	Age-Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate. Journal of Neurochemistry, 1993, 61, 1147-1150.	2.1	289
71	Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Human Molecular Genetics, 2010, 19, 3919-3935.	1.4	288
72	Increased oxidative damage to DNA in ALS patients. Free Radical Biology and Medicine, 2000, 29, 652-658.	1.3	286

#	Article	IF	Citations
73	Caspase-9 Activation Results in Downstream Caspase-8 Activation and Bid Cleavage in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease. Journal of Neuroscience, 2001, 21, 9519-9528.	1.7	282
74	Oxidative Damage in Huntington's Disease Pathogenesis. Antioxidants and Redox Signaling, 2006, 8, 2061-2073.	2.5	275
75	Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Annals of Neurology, 1997, 42, 261-264.	2.8	271
76	Morphologic and Histochemical Characteristics of a Spared Subset of Striatal Neurons in Huntington's Disease. Journal of Neuropathology and Experimental Neurology, 1987, 46, 12-27.	0.9	270
77	Mitochondria in Neurodegeneration: Bioenergetic Function in Cell Life and Death. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 231-245.	2.4	268
78	Are mitochondria critical in the pathogenesis of Alzheimer's disease?. Brain Research Reviews, 2005, 49, 618-632.	9.1	257
79	Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. Journal of Neurochemistry, 2004, 89, 1308-1312.	2.1	256
80	Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Research, 1987, 411, 162-166.	1.1	249
81	Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Annals of Neurology, 1997, 42, 326-334.	2.8	244
82	Mitochondrial Dysfunction and Oxidative Damage in Alzheimer's and Parkinson's Diseases and Coenzyme Q10as a Potential Treatment. Journal of Bioenergetics and Biomembranes, 2004, 36, 381-386.	1.0	244
83	Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntingtonâ€™s Disease. Journal of Neuroscience, 1996, 16, 3019-3025.	1.7	241
84	Matrix Metalloproteinase-3: A Novel Signaling Proteinase from Apoptotic Neuronal Cells That Activates Microglia. Journal of Neuroscience, 2005, 25, 3701-3711.	1.7	241
85	MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. NeuroReport, 2000, 11, 211-213.	0.6	238
86	Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: Correlation with PET, microdialysis, and behavioral data. Magnetic Resonance in Medicine, 1997, 38, 389-398.	1.9	237
87	Excitotoxicity and nitric oxide in parkinson's disease pathogenesis. Annals of Neurology, 1998, 44, S110-4.	2.8	236
88	Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle and Nerve, 2007, 35, 235-242.	1.0	235
89	Cytochemical Demonstration of Oxidative Damage in Alzheimer Disease by Immunochemical Enhancement of the Carbonyl Reaction with 2,4-Dinitrophenylhydrazine. Journal of Histochemistry and Cytochemistry, 1998, 46, 731-735.	1.3	234
90	Mitochondrial Approaches for Neuroprotection. Annals of the New York Academy of Sciences, 2008, 1147, 395-412.	1.8	232

#	Article	IF	Citations
91	Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Annals of Neurology, 2001, 49, 561-574.	2.8	230
92	Mutant Superoxide Dismutase 1 Forms Aggregates in the Brain Mitochondrial Matrix of Amyotrophic Lateral Sclerosis Mice. Journal of Neuroscience, 2005, 25, 2463-2470.	1.7	222
93	Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: Normal anatomy and alterations in alzheimer's disease. Annals of Neurology, 1988, 23, 105-114.	2.8	219
94	Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 651-663.	1.8	219
95	Selective sparing of NADPH-diaphorase-somatostatin-neuropeptide Y neurons in ischemic gerbil striatum. Annals of Neurology, 1990, 27, 620-625.	2.8	218
96	Impaired PGC-1Î± function in muscle in Huntington's disease. Human Molecular Genetics, 2009, 18, 3048-3065.	1.4	215
97	Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry, 2002, 79, 1246-1249.	2.1	214
98	Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. , 2000, 59, 133-154.		212
99	Lymphocyte Oxidative DNA Damage and Plasma Antioxidants in Alzheimer Disease. Archives of Neurology, 2002, 59, 794.	4.9	212
100	Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease. JAMA Neurology, 2014, 71, 141.	4.5	211
101	Basic Fibroblast Growth Factor Protects against Hypoxia-Ischemia and NMDA Neurotoxicity in Neonatal Rats. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 221-228.	2.4	210
102	Combination therapy with Coenzyme Q₁₀ and creatine produces additive neuroprotective effects in models of Parkinsonâ€™s and Huntingtonâ€™s Diseases. Journal of Neurochemistry, 2009, 109, 1427-1439.	2.1	210
103	Bioenergetic approaches for neuroprotection in Parkinson's disease. Annals of Neurology, 2003, 53, S39-S48.	2.8	209
104	The Energetics of Huntington's Disease. Neurochemical Research, 2004, 29, 531-546.	1.6	206
105	Neural mitochondrial Ca2+capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. Journal of Neurochemistry, 2006, 96, 1349-1361.	2.1	203
106	Cause and consequence: Mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 122-134.	1.8	203
107	Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. Journal of the Neurological Sciences, 1992, 108, 80-87.	0.3	201
108	Experimental therapeutics in transgenic mouse models of Huntington's disease. Nature Reviews Neuroscience, 2004, 5, 373-384.	4.9	201

#	Article	IF	Citations
109	Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Molecular and Chemical Neuropathology, 1997, 31, 53-64.	1.0	200
110	Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochemistry International, 2003, 43, 191-196.	1.9	200
111	Expression Profiling of Huntington's Disease Models Suggests That Brain-Derived Neurotrophic Factor Depletion Plays a Major Role in Striatal Degeneration. Journal of Neuroscience, 2007, 27, 11758-11768.	1.7	197
112	Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Experimental Neurology, 2005, 191, 331-336.	2.0	195
113	Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB Journal, 2009, 23, 2459-2466.	0.2	195
114	Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends in Neurosciences, 2010, 33, 541-549.	4.2	194
115	Differential sparing of somatostatin-neuropeptide y and cholinergic neurons following striatal excitotoxin lesions. Synapse, 1989, 3, 38-47.	0.6	193
116	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride Neurotoxicity Is Attenuated in Mice Overexpressing Bcl-2. Journal of Neuroscience, 1998, 18, 8145-8152.	1.7	193
117	Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. Journal of Neurochemistry, 2005, 94, 995-1004.	2.1	192
118	A pivotal role of matrix metalloproteinaseâ€3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB Journal, 2007, 21, 179-187.	0.2	191
119	Mechanisms of Reduced Striatal NMDA Excitotoxicity in Type I Nitric Oxide Synthase Knock-Out Mice. Journal of Neuroscience, 1997, 17, 6908-6917.	1.7	187
120	Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. Journal of Experimental Medicine, 2005, 202, 1163-1169.	4.2	187
121	Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Experimental Neurology, 2004, 188, 491-494.	2.0	186
122	Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiology of Disease, 2006, 21, 541-548.	2.1	185
123	Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Annals of Neurology, 1994, 36, 882-888.	2.8	183
124	Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's Disease. Journal of Neuroscience, 2004, 24, 10335-10342.	1.7	181
125	PGC-1Î±, mitochondrial dysfunction, and Huntington's disease. Free Radical Biology and Medicine, 2013, 62, 37-46.	1.3	180
126	Thalidomide and Lenalidomide Extend Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2006, 26, 2467-2473.	1.7	178

#	Article	IF	Citations
127	Uncoupling Protein 2 Prevents Neuronal Death Including that Occurring during Seizures: A Mechanism for Preconditioning. Endocrinology, 2003, 144, 5014-5021.	1.4	177
128	CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain. Neuron, 1995, 15, 1193-1201.	3.8	175
129	Celastrol Blocks Neuronal Cell Death and Extends Life in Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. Neurodegenerative Diseases, 2005, 2, 246-254.	0.8	175
130	Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radical Biology and Medicine, 2011, 51, 88-96.	1.3	173
131	Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 2003, 88, 576-582.	2.1	171
132	Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease. Journal of Neuroscience, 2016, 36, 6332-6351.	1.7	169
133	Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease, 2006, 22, 40-49.	2.1	165
134	Neuropeptides in neurological disease. Annals of Neurology, 1986, 20, 547-565.	2.8	162
135	1-Methyl-4-Phenylpyridinium Produces Excitotoxic Lesions in Rat Striatum as a Result of Impairment of Oxidative Metabolism. Journal of Neurochemistry, 1992, 58, 1975-1978.	2.1	162
136	The role of mitochondria in inherited neurodegenerative diseases. Journal of Neurochemistry, 2006, 97, 1659-1675.	2.1	161
137	Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease. Annals of Neurology, 1986, 20, 282-288.	2.8	157
138	Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Human Molecular Genetics, 2012, 21, 1124-1137.	1.4	157
139	Nonlinear Decrease over Time in N-Acetyl Aspartate Levels in the Absence of Neuronal Loss and Increases in Glutamine and Glucose in Transgenic Huntington's Disease Mice. Journal of Neurochemistry, 2008, 74, 2108-2119.	2.1	156
140	Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of Neurochemistry, 2003, 85, 1359-1367.	2.1	155
141	The Î±-Ketoglutarateâ€“Dehydrogenase Complex: A Mediator Between Mitochondria and Oxidative Stress in Neurodegeneration. Molecular Neurobiology, 2005, 31, 043-064.	1.9	154
142	Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14430-14435.	3.3	154
143	Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB Journal, 2010, 24, 4639-4647.	0.2	154
144	Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 2006, 98, 1141-1148.	2.1	153

#	Article	IF	Citations
145	Metabolomic analysis and signatures in motor neuron disease. Metabolomics, 2005, 1, 101-108.	1.4	152
146	3â€Nitropropionic Acid Neurotoxicity Is Attenuated in Copper/Zinc Superoxide Dismutase Transgenic Mice. Journal of Neurochemistry, 1995, 65, 919-922.	2.1	151
147	Mitochondria Targeted Peptides Protect Against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Neurotoxicity. Antioxidants and Redox Signaling, 2009, 11, 2095-2104.	2.5	151
148	PPAR: a therapeutic target in Parkinsonâ€™s disease. Journal of Neurochemistry, 2008, 106, 506-518.	2.1	150
149	Targeting Nrf2-Mediated Gene Transcription by Extremely Potent Synthetic Triterpenoids Attenuate Dopaminergic Neurotoxicity in the MPTP Mouse Model of Parkinson's Disease. Antioxidants and Redox Signaling, 2013, 18, 139-157.	2.5	150
150	NADPH Oxidase 1-Mediated Oxidative Stress Leads to Dopamine Neuron Death in Parkinson's Disease. Antioxidants and Redox Signaling, 2012, 16, 1033-1045.	2.5	148
151	Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radical Biology and Medicine, 2010, 49, 147-158.	1.3	147
152	Neuroprotective effects of creatine. Amino Acids, 2011, 40, 1305-1313.	1.2	147
153	Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiology of Disease, 2006, 22, 599-610.	2.1	146
154	Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription. PLoS ONE, 2009, 4, e5757.	1.1	146
155	Title is missing!. Molecular and Cellular Biochemistry, 1997, 174, 193-197.	1.4	145
156	Elevated â€œHydroxyl Radicalâ€•Generation In Vivo in an Animal Model of Amyotrophic Lateral Sclerosis. Journal of Neurochemistry, 1998, 71, 1321-1324.	2.1	145
157	Heterogeneous Topographic and Cellular Distribution of Huntingtin Expression in the Normal Human Neostriatum. Journal of Neuroscience, 1997, 17, 3052-3063.	1.7	143
158	Minocycline enhances MPTP toxicity to dopaminergic neurons. Journal of Neuroscience Research, 2003, 74, 278-285.	1.3	142
159	Remodeling Chromatin and Stress Resistance in the Central Nervous System: Histone Deacetylase Inhibitors as Novel and Broadly Effective Neuroprotective Agents. CNS and Neurological Disorders, 2005, 4, 41-50.	4.3	142
160	Metabolomic Profiling in LRRK2-Related Parkinson's Disease. PLoS ONE, 2009, 4, e7551.	1.1	142
161	Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Research, 2003, 964, 288-294.	1.1	141
162	Oxidative stress biomarkers in sporadic ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 177-183.	2.3	141

#	Article	IF	Citations
163	The Role of NADPH Oxidase 1â€“Derived Reactive Oxygen Species in Paraquat-Mediated Dopaminergic Cell Death. Antioxidants and Redox Signaling, 2009, 11, 2105-2118.	2.5	141
164	Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases. NeuroMolecular Medicine, 2008, 10, 275-290.	1.8	140
165	Manganese Superoxide Dismutase Overexpression Attenuates MPTP Toxicity. Neurobiology of Disease, 1998, 5, 253-258.	2.1	138
166	Pulse Inhibition of Histone Deacetylases Induces Complete Resistance to Oxidative Death in Cortical Neurons without Toxicity and Reveals a Role for Cytoplasmic p21^{waf1/cip1}in Cell Cycle-Independent Neuroprotection. Journal of Neuroscience, 2008, 28, 163-176.	1.7	138
167	Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. Journal of Experimental Medicine, 2012, 209, 2501-2513.	4.2	138
168	Coenzyme Q 10 as a Possible Treatment for Neurodegenerative Diseases. Free Radical Research, 2002, 36, 455-460.	1.5	137
169	Age and sex influence on oxidative damage and functional status in human skeletal muscle. Journal of Muscle Research and Cell Motility, 2001, 22, 345-351.	0.9	136
170	Antioxidants in Huntington's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 664-674.	1.8	136
171	Rewiring of Glutamine Metabolism Is a Bioenergetic Adaptation of Human Cells with Mitochondrial DNA Mutations. Cell Metabolism, 2018, 27, 1007-1025.e5.	7.2	135
172	Therapeutic effects of coenzyme Q₁₀ (CoQ₁₀) and reduced CoQ₁₀ in the MPTP model of Parkinsonism. Journal of Neurochemistry, 2008, 104, 1613-1621.	2.1	134
173	Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatric Disease and Treatment, 2009, 5, 597.	1.0	133
174	Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. BMC Neuroscience, 2009, 10, 109.	0.8	132
175	Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Annals of Neurology, 2005, 58, 258-265.	2.8	131
176	A postmortem study of amino acid neurotransmitters in Alzheimer's disease. Annals of Neurology, 1986, 20, 616-621.	2.8	130
177	Riluzole therapy in Huntington's disease (HD). Movement Disorders, 1999, 14, 326-330.	2.2	129
178	Neuroprotective Effects of L-Kynurenine on Hypoxiaâ€”Ischemia and NMDA Lesions in Neonatal Rats. Journal of Cerebral Blood Flow and Metabolism, 1992, 12, 400-407.	2.4	128
179	N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. NeuroReport, 2000, 11, 2491-2493.	0.6	128
180	PGC-1Î±, a New Therapeutic Target in Huntington's Disease?. Cell, 2006, 127, 465-468.	13.5	128

#	Article	IF	Citations
181	Coenzyme Q10 Decreases Amyloid Pathology and Improves Behavior in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 211-223.	1.2	127
182	Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Molecular Medicine, 2010, 2, 349-370.	3.3	124
183	Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Human Molecular Genetics, 2010, 19, 3190-3205.	1.4	124
184	Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiology of Aging, 2009, 30, 1587-1600.	1.5	123
185	Metabolic Dysfunction in Familial, but Not Sporadic, Amyotrophic Lateral Sclerosis. Journal of Neurochemistry, 1998, 71, 281-287.	2.1	122
186	Nitration of Hsp90 induces cell death. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1102-11.	3.3	122
187	Expression of MMP-2, MMP-9, and MMP-1 and Their Endogenous Counterregulators TIMP-1 and TIMP-2 in Postmortem Brain Tissue of Parkinson's Disease. Experimental Neurology, 2002, 178, 13-20.	2.0	121
188	Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Experimental Neurology, 2010, 225, 74-84.	2.0	121
189	Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Molecular and Cellular Neurosciences, 2013, 55, 101-114.	1.0	121
190	Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. Journal of Neurochemistry, 2001, 77, 383-390.	2.1	118
191	Mice Deficient in Group IV Cytosolic Phospholipase A₂ Are Resistant to MPTP Neurotoxicity. Journal of Neurochemistry, 1998, 71, 2634-2637.	2.1	117
192	PINK1 Defect Causes Mitochondrial Dysfunction, Proteasomal Deficit and Î±-Synuclein Aggregation in Cell Culture Models of Parkinson's Disease. PLoS ONE, 2009, 4, e4597.	1.1	116
193	Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Human Molecular Genetics, 2014, 23, 3716-3732.	1.4	115
194	Huntington's Disease of the Endocrine Pancreas: Insulin Deficiency and Diabetes Mellitus due to Impaired Insulin Gene Expression. Neurobiology of Disease, 2002, 11, 410-424.	2.1	114
195	Unexpected Lack of Hypersensitivity in LRRK2 Knock-Out Mice to MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine). Journal of Neuroscience, 2009, 29, 15846-15850.	1.7	114
196	Aminooxyacetic Acid Results in Excitotoxin Lesions by a Novel Indirect Mechanism. Journal of Neurochemistry, 1991, 57, 1068-1073.	2.1	113
197	A novel intracellular role of matrix metalloproteinaseâ€3 during apoptosis of dopaminergic cells. Journal of Neurochemistry, 2008, 106, 405-415.	2.1	113
198	Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle and Nerve, 2006, 33, 598-608.	1.0	112

#	Article	IF	Citations
199	Galanin immunoreactivity is increased in the nucleus basalis of meynert in Alzheimer's disease. Annals of Neurology, 1990, 28, 157-161.	2.8	110
200	Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinsonâ€™s disease. Neurobiology of Aging, 2004, 25, 71-81.	1.5	110
201	Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats. Neuroscience Letters, 1999, 259, 21-24.	1.0	108
202	Cytochrome C and Caspase-9 Expression in Huntington 's Disease. NeuroMolecular Medicine, 2002, 1, 183-196.	1.8	108
203	Prophylactic Creatine Administration Mediates Neuroprotection in Cerebral Ischemia in Mice. Journal of Neuroscience, 2004, 24, 5909-5912.	1.7	108
204	Neurochemistry and toxin models in HuntingtonÊ¼s disease. Current Opinion in Neurology, 1994, 7, 542-547.	1.8	107
205	Parkinsonism genes: culprits and clues. Journal of Neurochemistry, 2006, 99, 1062-1072.	2.1	106
206	Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q ₁₀ in parkinsonian patients. Neurology, 1998, 50, 793-795.	1.5	105
207	Lipoic acid improves survival in transgenic mouse models of Huntington's disease. NeuroReport, 2001, 12, 3371-3373.	0.6	105
208	Matrix metalloproteinase-9 regulates TNF-Î± and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Experimental Neurology, 2007, 205, 74-81.	2.0	105
209	Somatic mitochondrial DNA mutations in early parkinson and incidental lewy body disease. Annals of Neurology, 2012, 71, 850-854.	2.8	103
210	Does the mitochondrial genome play a role in the etiology of Alzheimerâ€™s disease?. Human Genetics, 2006, 119, 241-254.	1.8	102
211	Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Experimental Neurology, 1995, 132, 279-283.	2.0	101
212	Superoxide Dismutase Concentration and Activity in Familial Amyotrophic Lateral Sclerosis. Journal of Neurochemistry, 1995, 64, 2366-2369.	2.1	101
213	Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease. Annals of Neurology, 1986, 20, 489-495.	2.8	99
214	Global ischemia induces NMDA receptor-mediated c-fos expression in neurons resistant to injury in gerbil hippocampus. Brain Research, 1991, 542, 343-347.	1.1	99
215	Chapter 21 Glutamate toxicity in chronic neurodegenerative disease. Progress in Brain Research, 1998, 116, 331-347.	0.9	99
216	Coenzyme Q₁₀ administration and its potential for treatment of neurodegenerative diseases. BioFactors, 1999, 9, 261-266.	2.6	99

#	Article	IF	Citations
217	Triterpenoid CDDOâ€methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimerâ€™s disease. Journal of Neurochemistry, 2009, 109, 502-512.	2.1	99
218	Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Research Bulletin, 1992, 28, 233-238.	1.4	98
219	NGF, BDNF and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals. Brain Research, 1996, 713, 178-185.	1.1	97
220	Bioenergetics in Huntington's Disease. Annals of the New York Academy of Sciences, 1999, 893, 203-213.	1.8	97
221	Frontal Lobe Dysfunction in Progressive Supranuclear Palsy. Journal of Neurochemistry, 2001, 74, 878-881.	2.1	95
222	Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death and Differentiation, 1998, 5, 847-857.	5.0	93
223	A possible role of coenzyme Q₁₀ in the etiology and treatment of Parkinson's disease. BioFactors, 1999, 9, 267-272.	2.6	93
224	A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin. Human Molecular Genetics, 2013, 22, 3869-3882.	1.4	93
225	Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3â€nitropropionic acid neurotoxicity. Journal of Neurochemistry, 2004, 88, 1352-1360.	2.1	92
226	Role of Matrix Metalloproteinase 3-mediated Î±-Synuclein Cleavage in Dopaminergic Cell Death. Journal of Biological Chemistry, 2011, 286, 14168-14177.	1.6	92
227	Neuroprotective Effects of Phenylbutyrate Against MPTP Neurotoxicity. NeuroMolecular Medicine, 2004, 5, 235-242.	1.8	91
228	Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Research, 1994, 647, 161-166.	1.1	90
229	Clinically Approved Heterocyclics Act on a Mitochondrial Target and Reduce Stroke-induced Pathology. Journal of Experimental Medicine, 2004, 200, 211-222.	4.2	90
230	Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 2003, 85, 142-150.	2.1	89
231	The Role of Mitochondria in the Pathogenesis of Neurodegenerative Diseases. Brain Pathology, 2000, 10, 462-472.	2.1	89
232	Primary Lateral Sclerosis. Archives of Neurology, 1981, 38, 630.	4.9	88
233	NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. NeuroReport, 1993, 4, 387-390.	0.6	88
234	Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxiaâ€“telangiectasia mice. Free Radical Biology and Medicine, 2004, 36, 938-942.	1.3	88

#	Article	IF	Citations
235	Parkinson's disease: a model dilemma. Nature, 2010, 466, S8-S10.	13.7	88
236	MicroRNA-Related Cofilin Abnormality in Alzheimer's Disease. PLoS ONE, 2010, 5, e15546.	1.1	87
237	Inhibition of Prolyl Hydroxylase Protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurotoxicity. Journal of Biological Chemistry, 2009, 284, 29065-29076.	1.6	86
238	Somatostatin and neuropeptide Y concentrations in pathologically graded cases of huntington's disease. Annals of Neurology, 1988, 23, 562-569.	2.8	85
239	Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S189-S194.	1.1	85
240	Detection of dopaminergic cell loss and neural transplantation using pharmacological MRI, PET and behavioral assessment. NeuroReport, 1999, 10, 2881-2886.	0.6	84
241	Basic Fibroblast Growth Factor Protects against Excitotoxicity and Chemical Hypoxia in Both Neonatal and Adult Rats. Journal of Cerebral Blood Flow and Metabolism, 1995, 15, 619-623.	2.4	83
242	Safety and tolerability of highâ€dosage coenzyme Q₁₀ in Huntington's disease and healthy subjects. Movement Disorders, 2010, 25, 1924-1928.	2.2	82
243	Non-Invasive Neurochemical Analysis of Focal Excitotoxic Lesions in Models of Neurodegenerative Illness Using Spectroscopic Imaging. Journal of Cerebral Blood Flow and Metabolism, 1996, 16, 450-461.	2.4	80
244	Oxidative damage as an early marker of Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2005, 26, 585-586.	1.5	80
245	Transgenic mice expressing a dominant negative mutant interleukin-1Î² converting enzyme show resistance to MPTP neurotoxicity. NeuroReport, 1999, 10, 635-638.	0.6	79
246	Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Annals of Neurology, 2001, 50, 112-116.	2.8	79
247	Increased Vulnerability to 3â€Nitropropionic Acid in an Animal Model of Huntington's Disease. Journal of Neurochemistry, 1998, 71, 2642-2644.	2.1	79
248	Conditional transgenic mice expressing C-terminally truncated human Î±-synuclein (Î±Syn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Molecular Neurodegeneration, 2009, 4, 34.	4.4	79
249	Glutamate-, glutaminase-, and taurine-immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease. Annals of Neurology, 1991, 29, 162-167.	2.8	78
250	Neuroprotective Effects of Synaptic Modulation in Huntington's Disease R6/2 Mice. Journal of Neuroscience, 2007, 27, 12908-12915.	1.7	78
251	Mitochondria and Antioxidant Targeted Therapeutic Strategies for Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, S633-S643.	1.2	78
252	The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis. Alzheimer's and Dementia, 2023, 19, 333-342.	0.4	78

#	Article	IF	Citations
253	Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiology of Aging, 2005, 26, 1343-1355.	1.5	77
254	NÎµ-(Î³-l-Glutamyl)-l-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. Journal of Neurochemistry, 2008, 79, 1109-1112.	2.1	77
255	Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. Human Molecular Genetics, 2012, 21, 5091-5105.	1.4	77
256	Mitochondria and Neurodegeneration. Novartis Foundation Symposium, 2007, 287, 183-196.	1.2	77
257	Developmental changes in brain kynurenic acid concentrations. Developmental Brain Research, 1992, 68, 136-139.	2.1	75
258	Mitochondrial dysfunction in movement disorders. Current Opinion in Neurology, 1994, 7, 333-339.	1.8	75
259	Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy. Journal of Neuroscience Research, 2001, 66, 1028-1034.	1.3	75
260	Increased oxidative damage to DNA in an animal model of amyotrophic lateral sclerosis. Free Radical Research, 2005, 39, 383-388.	1.5	75
261	Additive Neuroprotective Effects of Creatine and a Cyclooxygenase 2 Inhibitor Against Dopamine Depletion in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease. Journal of Molecular Neuroscience, 2003, 21, 191-198.	1.1	74
262	A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiology of Disease, 2004, 17, 250-259.	2.1	74
263	Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. Journal of Neurochemistry, 2005, 95, 553-562.	2.1	74
264	Preferential PPAR-Î± activation reduces neuroinflammation, and blocks neurodegenerationin vivo. Human Molecular Genetics, 2016, 25, 317-327.	1.4	73
265	Striatal Malonate Lesions Are Attenuated in Neuronal Nitric Oxide Synthase Knockout Mice. Journal of Neurochemistry, 1996, 67, 430-433.	2.1	72
266	Integrative role of cPLA2with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 2005, 93, 403-411.	2.1	72
267	Lenalidomide (RevlimidÂ®) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Experimental Neurology, 2009, 220, 191-197.	2.0	72
268	The oxidative damage theory of aging. Clinical Neuroscience Research, 2003, 2, 305-315.	0.8	71
269	Characterization and mechanism of glutamate neurotoxicity in primary striatal cultures. Brain Research, 1990, 521, 254-264.	1.1	69
270	Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis. Annals of Neurology, 2000, 47, 447-455.	2.8	69

#	Article	IF	Citations
271	Sequence Analysis of the Entire Mitochondrial Genome in Parkinson's Disease. Biochemical and Biophysical Research Communications, 2002, 290, 1593-1601.	1.0	69
272	Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. Brain, 2013, 136, 2432-2443.	3.7	69
273	Î²-amyloid 42 accumulation in the lumbar spinal cord motor neurons of amyotrophic lateral sclerosis patients. Neurobiology of Disease, 2005, 19, 340-347.	2.1	68
274	Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. International Psychogeriatrics, 2008, 20, 67-76.	0.6	68
275	Multinuclear Magnetic Resonance Spectroscopy for in Vivo Assessment of Mitochondrial Dysfunction in Parkinson's Disease. Annals of the New York Academy of Sciences, 2008, 1147, 206-220.	1.8	67
276	Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. Human Molecular Genetics, 2017, 26, ddw429.	1.4	67
277	In Vivo Regulation of Oxidative Phosphorylation in Cells Harboring a Stop-codon Mutation in Mitochondrial DNA-encoded Cytochrome c Oxidase Subunit I. Journal of Biological Chemistry, 2001, 276, 46925-46932.	1.6	66
278	Topographical dopamine and serotonin distribution and turnover in rat striatum. Brain Research, 1985, 358, 10-15.	1.1	65
279	Neurotoxicity and behavioral deficits associated with Septinâ€ƒ5 accumulation in dopaminergic neurons. Journal of Neurochemistry, 2005, 94, 1040-1053.	2.1	65
280	MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiology of Disease, 2007, 26, 312-322.	2.1	64
281	Huntington's disease, energy, and excitotoxicity. Neurobiology of Aging, 1994, 15, 275-276.	1.5	63
282	Oxidative Damage in Neurodegenerative Diseases. Neuroscientist, 1997, 3, 21-27.	2.6	63
283	Therapeutic Efficacy of EGb761 (Gingko biloba Extract) in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Molecular Neuroscience, 2001, 17, 89-96.	1.1	62
284	Effects of lesions on somatostatin-like immunoreactivity in the rat striatum. Brain Research, 1983, 266, 67-73.	1.1	60
285	Evidence for Oxidative Stress in the Subthalamic Nucleus in Progressive Supranuclear Palsy. Journal of Neurochemistry, 2002, 73, 881-884.	2.1	60
286	Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. NeuroReport, 2000, 11, 1265-1268.	0.6	59
287	The matrix metalloproteinases inhibitor Ro 26-2853 extends survival in transgenic ALS mice. Experimental Neurology, 2006, 200, 166-171.	2.0	59
288	Matrix Metalloproteinase-9 Is Elevated in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonism in Mice. NeuroMolecular Medicine, 2004, 5, 119-132.	1.8	58

#	Article	IF	Citations
289	Mitochondrial dihydrolipoyl succinyltransferase deficiency accelerates amyloid pathology and memory deficit in a transgenic mouse model of amyloid deposition. Free Radical Biology and Medicine, 2009, 47, 1019-1027.	1.3	58
290	Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. Human Molecular Genetics, 2018, 27, 2874-2892.	1.4	58
291	The effect of amphetamine on the in vivo release of dopamine, somatostatin and neuropeptide Y from rat caudate nucleus. Brain Research, 1987, 411, 200-203.	1.1	57
292	Age-related disruption of classical conditioning: A model systems approach to memory disorders. Neurobiology of Aging, 1988, 9, 535-546.	1.5	57
293	Improved Therapeutic Window for Treatment of Histotoxic Hypoxia with a Free Radical Spin Trap. Journal of Cerebral Blood Flow and Metabolism, 1995, 15, 948-952.	2.4	57
294	Increased 3-nitrotyrosine in brains of Apo E-deficient mice. Brain Research, 1996, 718, 181-184.	1.1	57
295	The neurotoxicity of amyloid beta protein in aged primates. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 1-9.	1.4	57
296	Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice. Free Radical Biology and Medicine, 2002, 32, 920-926.	1.3	57
297	The negative impact ofÎ±â€ketoglutarate dehydrogenase complex deficiency on matrix substrateâ€level phosphorylation. FASEB Journal, 2013, 27, 2392-2406.	0.2	57
298	NGF attenuates 3-nitrotyrosine formation in a 3-NP model of HuntingtonÊ¼s disease. NeuroReport, 1996, 7, 2639-2642.	0.6	56
299	Oxidative stress is attenuated in mice overexpressing BCL-2. Neuroscience Letters, 1999, 262, 33-36.	1.0	56
300	Effects of Coenzyme Q₁₀ in Huntington's disease and early Parkinson's disease. BioFactors, 2003, 18, 153-161.	2.6	56
301	Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry, 2004, 86, 267-272.	2.1	56
302	Regional somatostatin distribution in the rat striatum. Brain Research, 1983, 278, 103-108.	1.1	55
303	Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiology of Disease, 2004, 15, 610-617.	2.1	54
304	Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease. Human Molecular Genetics, 2012, 21, 3474-3488.	1.4	54
305	The cortical lesion of Huntington's disease: Further neurochemical characterization, and reproduction of some of the histological and neurochemical features byN-methyl-D-aspartate lesions of rat cortex. Annals of Neurology, 1992, 32, 526-534.	2.8	53
306	The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 2007, 102, 991-1000.	2.1	53

#	Article	IF	Citations
307	Determination of Coenzyme A and Acetyl-Coenzyme A in Biological Samples Using HPLC with UV Detection. Molecules, 2017, 22, 1388.	1.7	53
308	A detailed examination of substance P in pathologically graded cases of Huntington's disease. Journal of the Neurological Sciences, 1988, 84, 51-61.	0.3	50
309	Genetically Decreased Spinal Cord Copper Concentration Prolongs Life in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2004, 24, 7945-7950.	1.7	50
310	Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Experimental Neurology, 2008, 211, 311-314.	2.0	50
311	Impaired Brain Energy Metabolism in the BACHD Mouse Model of Huntington's Disease: Critical Role of Astrocyteâ€“Neuron Interactions. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1500-1510.	2.4	50
312	Mitochondrial therapies for Parkinson's disease. Movement Disorders, 2010, 25, S155-60.	2.2	49
313	Determination of Neurotransmitter Levels in Models of Parkinsonâ€™s Disease by HPLC-ECD. Methods in Molecular Biology, 2011, 793, 401-415.	0.4	49
314	Mitochondrial Permeability Transition Pore Component Cyclophilin D Distinguishes Nigrostriatal Dopaminergic Death Paradigms in the MPTP Mouse Model of Parkinson's Disease. Antioxidants and Redox Signaling, 2012, 16, 855-868.	2.5	49
315	Concordant Signaling Pathways Produced by Pesticide Exposure in Mice Correspond to Pathways Identified in Human Parkinson's Disease. PLoS ONE, 2012, 7, e36191.	1.1	49
316	IDIOPATHIC CRANIAL POLYNEUROPATHY. Brain, 1987, 110, 197-211.	3.7	48
317	Therapeutic Effects of Coenzyme Q10 in Neurodegenerative Diseases. Methods in Enzymology, 2004, 382, 473-487.	0.4	48
318	Diffusion tensor imaging in the diagnosis of primary lateral sclerosis. Journal of Magnetic Resonance Imaging, 2004, 19, 34-39.	1.9	48
319	The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. , 1997, , 193-197.		48
320	Increased affinity for copper mediated by cysteine 111 in forms of mutant superoxide dismutase 1 linked to amyotrophic lateral sclerosis. Free Radical Biology and Medicine, 2007, 42, 1534-1542.	1.3	47
321	Behavioral Improvement after Chronic Administration of Coenzyme Q10 in P301S Transgenic Mice. Journal of Alzheimer's Disease, 2012, 28, 173-182.	1.2	47
322	PGCâ€1Î±: overexpression exacerbates Î²â€amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease. FASEB Journal, 2014, 28, 1745-1755.	0.2	47
323	A comparison of somatostatin and neuropeptide Y distribution in monkey brain. Brain Research, 1987, 405, 213-219.	1.1	46
324	Mitochondrial Aconitase is a Transglutaminase 2 Substrate: Transglutamination is a Probable Mechanism Contributing to High-Molecular-Weight Aggregates of Aconitase and Loss of Aconitase Activity in Huntington Disease Brain. Neurochemical Research, 2005, 30, 1245-1255.	1.6	46

#	Article	IF	Citations
325	Galanin-Like Immunoreactivity Is Unchanged in Alzheimer's Disease and Parkinson's Disease Dementia Cerebral Cortex. Journal of Neurochemistry, 1988, 51, 1935-1941.	2.1	45
326	Homocysteic acid lesions in rat striatum spare somatostatinâ€";Neuropeptide Y (NADPH-diaphorase) neurons. Neuroscience Letters, 1990, 108, 36-42.	1.0	44
327	The effect of peripheral loading with kynurenine and probenecid on extracellular striatal kynurenic acid concentrations. Neuroscience Letters, 1992, 146, 115-118.	1.0	44
328	Mice Overexpressing 70-kDa Heat Shock Protein Show Increased Resistance to Malonate and 3-Nitropropionic Acid. Experimental Neurology, 2002, 176, 262-265.	2.0	44
329	The Mitochondrial Permeability Transition as a Target for Neuroprotection. Journal of Bioenergetics and Biomembranes, 2004, 36, 309-312.	1.0	44
330	NOS knockouts and neuroprotection. Nature Medicine, 1999, 5, 1354-1355.	15.2	43
331	Malonate and 3-Nitropropionic Acid Neurotoxicity Are Reduced in Transgenic Mice Expressing a Caspase-1 Dominant-Negative Mutant. Journal of Neurochemistry, 2002, 75, 847-852.	2.1	43
332	Molecular insights into Parkinson's disease. F1000 Medicine Reports, 2011, 3, 7.	2.9	43
333	Usefulness of Proton and Phosphorus MR Spectroscopic Imaging for Early Diagnosis of Parkinson's Disease. Journal of Neuroimaging, 2015, 25, 105-110.	1.0	43
334	A comparison of regional somatostatin and neuropeptide Y distribution in rat striatum and brain. Brain Research, 1986, 377, 240-245.	1.1	42
335	Comparative behavioral and neurochemical studies with striatal kainic acid- or quinolinic acid-lesioned rats. Pharmacology Biochemistry and Behavior, 1991, 39, 473-478.	1.3	42
336	A neuroprotective role of the human uncoupling protein 2 (hUCP2) in a Drosophila Parkinson's Disease model. Neurobiology of Disease, 2012, 46, 137-146.	2.1	42
337	Altered succinylation of mitochondrial proteins, APP and tau in Alzheimerâ€™s disease. Nature Communications, 2022, 13, 159.	5.8	42
338	Distribution of galanin-like immunoreactivity in baboon brain. Peptides, 1988, 9, 847-851.	1.2	41
339	Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice. Journal of the Neurological Sciences, 2006, 251, 44-49.	0.3	41
340	Iodoacetate Produces Striatal Excitotoxic Lesions. Journal of Neurochemistry, 1997, 69, 285-289.	2.1	40
341	A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. Experimental Neurology, 2005, 191, 86-93.	2.0	40
342	Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. Annals of Neurology, 1988, 24, 647-650.	2.8	39

#	Article	IF	Citations
343	Behavioral deficits and progressive neuropathology in progranulinâ€deficient mice: a mouse model of frontotemporal dementia. FASEB Journal, 2010, 24, 4639-4647.	0.2	39
344	Expression and activity of antioxidants in the brain in progressive supranuclear palsy. Brain Research, 2002, 930, 170-181.	1.1	38
345	3-Acetylpyridine Produces Age-Dependent Excitotoxic Lesions in Rat Striatum. Journal of Cerebral Blood Flow and Metabolism, 1994, 14, 1024-1029.	2.4	37
346	Prospects for neuroprotective therapies in prodromal Huntington's disease. Movement Disorders, 2014, 29, 285-293.	2.2	37
347	Excitotoxin lesions do not mimic the alteration of somatostatin in Huntington's disease. Brain Research, 1985, 361, 135-145.	1.1	36
348	Somatostatin-281â€“12-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Brain Research, 1986, 368, 380-383.	1.1	35
349	Intracerebroventricular injection of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behavior in rats. Brain Research Bulletin, 1990, 25, 623-627.	1.4	35
350	Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntingtonâ€™s disease. Human Molecular Genetics, 2016, 25, 2269-2282.	1.4	35
351	Aberrant regulation of the <scp>GSK</scp> â€3Î²/ <scp>NRF</scp> 2 axis unveils a novel therapy for adrenoleukodystrophy. EMBO Molecular Medicine, 2018, 10, .	3.3	35
352	Delayed administration of basic fibroblast growth factor protects against N-methyl-D-aspartate neurotoxicity in neonatal rats. European Journal of Pharmacology, 1993, 232, 295-297.	1.7	34
353	3-Nitropropionic acid-induced neurotoxicity - assessed by ultra high resolution positron emission tomography with comparison to magnetic resonance spectroscopy. Journal of Neurochemistry, 2004, 89, 1206-1214.	2.1	33
354	Oxidative Metabolism. Annals of the New York Academy of Sciences, 2000, 924, 164-169.	1.8	33
355	Truncated Peroxisome Proliferator-Activated Receptor-Î³ Coactivator 1Î± Splice Variant Is Severely Altered in Huntingtonâ€™s Disease. Neurodegenerative Diseases, 2011, 8, 496-503.	0.8	32
356	Biomarkers of Parkinson's disease and Dementia with Lewy bodies. Progress in Neurobiology, 2011, 95, 601-613.	2.8	32
357	Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson's disease. European Journal of Neuroscience, 2019, 49, 525-532.	1.2	32
358	Dysregulation of the Levels of Matrix Metalloproteinases and Tissue Inhibitors of Matrix Metalloproteinases in the Early Phase of Cerebral Ischemia. Stroke, 2003, 34, e37-8; author reply e37-8.	1.0	31
359	Implications of neuropeptides in neurological diseases. Peptides, 1984, 5, 255-262.	1.2	29
360	Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in Ï0 cells. Experimental Neurology, 2003, 179, 229-235.	2.0	29

#	Article	IF	Citations
361	PGC-1Î±, Sirtuins and PARPs in Huntingtonâ€™s Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All. Neurochemical Research, 2019, 44, 2423-2434.	1.6	29
362	Stress-induced mitochondrial depolarization and oxidative damage in PSP cybrids. Brain Research, 2002, 951, 31-35.	1.1	28
363	Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiology of Disease, 2006, 24, 455-465.	2.1	27
364	Depletion of striatal somatostatin by local cysteamine injection. Brain Research, 1984, 308, 319-324.	1.1	26
365	Reductions in the mitochondrial enzyme Î±â€ketoglutarate dehydrogenase complex in neurodegenerative disease â€“ beneficial or detrimental?. Journal of Neurochemistry, 2016, 139, 823-838.	2.1	26
366	Neuroprotective Effects of Free Radical Scavengers and Energy Repletion in Animal Models of Neurodegenerative Disease. Annals of the New York Academy of Sciences, 1995, 765, 100-110.	1.8	25
367	Decreased Striatal Dopamine Release Underlies Increased Expression of Long-Term Synaptic Potentiation at Corticostriatal Synapses 24 h after 3-Nitropropionic-Acid-Induced Chemical Hypoxia. Journal of Neuroscience, 2008, 28, 9585-9597.	1.7	25
368	DJ-1 Cleavage by Matrix Metalloproteinase 3 Mediates Oxidative Stress-Induced Dopaminergic Cell Death. Antioxidants and Redox Signaling, 2011, 14, 2137-2150.	2.5	25
369	Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. Annals of Neurology, 1997, 41, 540-547.	2.8	24
370	Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy. Journal of the Neurological Sciences, 2004, 218, 39-45.	0.3	24
371	Mice deficient in dihydrolipoyl succinyl transferase show increased vulnerability to mitochondrial toxins. Neurobiology of Disease, 2009, 36, 320-330.	2.1	24
372	Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes. Brain Research, 1986, 397, 386-388.	1.1	23
373	Effects of lesions in the amygdala and periventricular hypothalamus on striatal somatostatin-like immunoreactivity. Brain Research, 1985, 330, 309-316.	1.1	22
374	Apocynin administration does not improve behavioral and neuropathological deficits in a transgenic mouse model of Alzheimer's disease. Neuroscience Letters, 2011, 492, 150-154.	1.0	22
375	Substance P-like immunoreactivity in brains with pathological features of Parkinson's and Alzheimer's diseases. Brain Research, 1989, 486, 387-390.	1.1	21
376	Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Neurobiology of Disease, 2005, 20, 701-708.	2.1	21
377	A Randomized Study of the Bioavailability of Different Formulations of Coenzyme Q₁₀ (Ubiquinone). Journal of Clinical Pharmacology, 2007, 47, 1580-1586.	1.0	21
378	Somatostatin and neuropeptide Y immunoreactivity in parkinson's disease dementia with alzheimer's changes. Synapse, 1988, 2, 463-467.	0.6	20

#	Article	IF	Citations
379	Effects of aging on quinolinic acid lesions in rat striatum. Brain Research, 1991, 562, 276-280.	1.1	20
380	Sex differences in cerebral energy metabolism in Parkinson's disease: A phosphorus magnetic resonance spectroscopic imaging study. Parkinsonism and Related Disorders, 2014, 20, 545-548.	1.1	20
381	Characterization of a Parkinsonâ€™s disease rat model using an upgraded paraquat exposure paradigm. European Journal of Neuroscience, 2020, 52, 3242-3255.	1.2	20
382	Somatostatin and neuropeptide Y are unaltered in the amygdala in schizophrenia. Neurochemical Pathology, 1987, 6, 169-176.	1.1	19
383	Multiple Cranial-Nerve Palsies â€” A Diagnostic Challenge. New England Journal of Medicine, 1990, 322, 461-463.	13.9	19
384	Hugging tight in Huntington's. Nature Medicine, 2011, 17, 245-246.	15.2	19
385	Reduced concentrations of arginine vasopressin and MHPG in lumbar CSF of patients with Korsakoff's psychosis. Life Sciences, 1986, 38, 2301-2306.	2.0	18
386	Toxin-induced mitochondrial dysfunction. International Review of Neurobiology, 2002, 53, 243-279.	0.9	17
387	Coordinate Regulation of Mature Dopaminergic Axon Morphology by Macroautophagy and the PTEN Signaling Pathway. PLoS Genetics, 2013, 9, e1003845.	1.5	17
388	Simultaneous determination of tricarboxylic acid cycle metabolites by high-performance liquid chromatography with ultraviolet detection. Analytical Biochemistry, 2016, 503, 8-10.	1.1	16
389	Huntington's disease, behavioral disturbances, and kynurenines: Preclinical findings and therapeutic perspectives. Biological Psychiatry, 1996, 39, 1061-1063.	0.7	15
390	Leucine-rich repeat kinase 2: A new player with a familiar theme for Parkinson's disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16535-16536.	3.3	15
391	Neuroprotective and neurorestorative strategies for neuronal injury. Neurotoxicity Research, 2000, 2, 71-84.	1.3	14
392	Large stem cell grafts could lead to erroneous interpretations of behavioral results?. Nature Medicine, 2007, 13, 118-119.	15.2	14
393	Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau. Human Molecular Genetics, 2015, 24, 3545-3556.	1.4	14
394	Effect of cysteamine on somatostatin and neuropeptide Y in rat striatum and cortical synaptosomes. Brain Research, 1987, 401, 359-364.	1.1	13
395	The Cerebral Metabolic Consequences of Nitric Oxide Synthase Deficiency: Glucose Utilization in Endothelial and Neuronal Nitric Oxide Synthase Null Mice. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 144-148.	2.4	13
396	The Effect of Coenzyme Q10 Therapy in Parkinson Disease Could Be Symptomaticâ€”Reply. Archives of Neurology, 2003, 60, 1172.	4.9	13

#	Article	IF	Citations
397	Neuroprotective Effects of Oral Administration of Triacetyluridine Against MPTP Neurotoxicity. NeuroMolecular Medicine, 2005, 6, 087-092.	1.8	13
398	Less stress, longer life. Nature Medicine, 2005, 11, 598-599.	15.2	13
399	N-iminoethyl-l-lysine improves memory and reduces amyloid pathology in a transgenic mouse model of amyloid deposition. Neurochemistry International, 2010, 56, 345-351.	1.9	13
400	Amino acid and neuropeptide neurotransmitters in Huntington's disease cerebellum. Brain Research, 1988, 454, 393-396.	1.1	12
401	Prospects for redox-based therapy in neurodegenerative diseases. Neurotoxicity Research, 2000, 2, 229-237.	1.3	12
402	Huntington's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 106, 507-526.	1.0	12
403	Poison and antidote: A novel model to study pathogenesis and therapy of LHON. Annals of Neurology, 2004, 56, 171-172.	2.8	11
404	Highâ€dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy. Brain Pathology, 2020, 30, 945-963.	2.1	11
405	Huntington's Disease and Neurotoxins. Annals of the New York Academy of Sciences, 1992, 648, 169-175.	1.8	10
406	Commentary on â€œAlpha-synuclein and mitochondria: a tangled skeinâ€• Experimental Neurology, 2004, 186, 109-111.	2.0	10
407	Isotope-reinforced polyunsaturated fatty acids improve Parkinsonâ€™s disease-like phenotype in rats overexpressing Î±-synuclein. Acta Neuropathologica Communications, 2020, 8, 220.	2.4	10
408	Changes of Coenzyme A and Acetyl-Coenzyme A Concentrations in Rats after a Single-Dose Intraperitoneal Injection of Hepatotoxic Thioacetamide Are Not Consistent with Rapid Recovery. International Journal of Molecular Sciences, 2020, 21, 8918.	1.8	10
409	Inability of ?-amyloid (25-35) to bind to central nervous system neurokinin 1 receptors. Drug Development Research, 1992, 27, 441-444.	1.4	9
410	Area-Specific Differences in OH8dG and mtDNA4977 Levels in Alzheimer Disease Patients and Aged Controls. Rejuvenation Research, 1999, 2, 209-216.	0.2	9
411	Toxic animal models. , 2005, , 196-221.		9
412	Merging mitochondria for neuronal survival. Nature Medicine, 2007, 13, 1140-1141.	15.2	9
413	HPLC determination of Î±-ketoglutaramate [5-amino-2,5-dioxopentanoate] in biological samples. Analytical Biochemistry, 2016, 494, 52-54.	1.1	9
414	Mechanisms of Neuronal Degeneration in Huntingtonâ€™s Disease. Advances in Behavioral Biology, 1994, , 149-161.	0.2	9

#	Article	IF	Citations
415	The Role of Oxidative Processes and Metal Ions in Aging and Alzheimerâ€™s Disease. , 1997, , 237-275.		9
416	Acute and longâ€term response of dopamine nigrostriatal synapses to a single, lowâ€dose episode of 3â€nitropropionic acidâ€mediated chemical hypoxia. Synapse, 2011, 65, 339-350.	0.6	8
417	Neuropeptides in Alzheimer's Disease: Clinical implications. Neurologic Clinics, 1986, 4, 753-768.	0.8	7
418	Promethazine protects against 3-nitropropionic acid-induced neurotoxicity. Neurochemistry International, 2010, 56, 208-212.	1.9	6
419	Hunting-ton for New Proteases: MMPs as the New Target?. Neuron, 2010, 67, 171-173.	3.8	6
420	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	6
421	New techniques for investigating mitochondrial DNA in neurodegenerative diseases. Neurology, 1997, 49, 907-908.	1.5	5
422	Limited-time exposure to mitochondrial toxins may lead to chronic progressive neurodegenerative diseases. Movement Disorders, 2000, 15, 434-435.	2.2	5
423	Muscling In on PGC-1Î± for Improved Quality of Life in ALS. Cell Metabolism, 2012, 15, 567-569.	7.2	5
424	Oral Repeated-Dose Toxicity Studies of Coenzyme Q10 in Beagle Dogs. International Journal of Toxicology, 2012, 31, 58-69.	0.6	4
425	Therapeutic effects of nitric oxide synthase inhibition in neuronal injury. , 1996, , 91-101.		4
426	Metabolomics: A New Approach Towards Identifying Biomarkers and Therapeutic Targets in CNS Disorders. , 2005, , 45-61.		3
427	Huntington's disease. , 2005, , 847-860.		2
428	Calcium binding proteins in selective vulnerability of motor neurons. , 2005, , 65-79.		2
429	Introduction and Historical Notes. , 2004, , 1-9.		2
430	Amyotrophic lateral sclerosis: Transgenic model and novel neuroprotective agent. Neuroscience Research Communications, 2000, 26, 215-226.	0.2	1
431	Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry, 2003, 87, 272-272.	2.1	1
432	Neurodegenerative disease and the repair of oxidatively damaged DNA. , 2005, , 131-140.		1

#	Article	IF	Citations
433	Excitoxicity and excitatory amino acid antagonists in chronic neurodegenerative diseases. , 2005, , 44-56.		1
434	Excitotoxicity. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 553-569.	1.0	1
435	The urokinase system of plasminogen activator plays a role in amyotrophic lateral sclerosis (ALS) pathogenesis. Experimental Neurology, 2008, 211, 332-333.	2.0	1
436	Neuropeptide Abnormalities in Alzheimerâ€™s and Huntingtonâ€™s Diseases. , 1988, , 199-212.		1
437	Systemic Administration of 3-Nitropropionic Acid. , 2000, , 301-332.		1
438	The Neuroprotective Properties of Creatine in Animal Models of Neurodegenerative Diseases. Medical Science Symposia Series, 2000, , 101-118.	0.0	1
439	Mitochondrial Dysfunction and Alzheimerâ€™s Disease. Advances in Behavioral Biology, 1998, , 59-66.	0.2	1
440	Huntington's Disease. , 2001, , 711-725.		0
441	Biological oxidants and therapeutic antioxidants. , 2005, , 18-32.		0
442	Mitochondria, metabolic inhibitors and neurodegeneration. , 2005, , 33-43.		0
443	Apoptosis in neurodegenerative diseases. , 2005, , 80-93.		0
444	Protein misfolding and cellular defense mechanisms in neurodegenerative diseases. , 2005, , 108-130.		0
445	Magnetic resonance spectroscopy of neurodegenerative illness. , 2005, , 301-326.		0
446	Current and potential therapeutics in motor neuron diseases. , 2005, , 772-793.		0
447	Dentatorubral-pallidoluysian atrophy (DRPLA): model for Huntington's disease and other polyglutamine diseases. , 2005, , 861-870.		0
448	Disorders of the mitochondrial respiratory chain. , 2005, , 909-926.		0
449	Endogenous free radicals and antioxidants in the brain. , 2005, , 3-17.		0
450	Copper and zinc in Alzheimer's disease and amyotrophic lateral sclerosis. , 2005, , 157-165.		0

#	Article	IF	Citations
451	Current and potential treatments of Parkinson's disease. , 2005, , 612-622.		0
452	Brain iron disorders. , 2005, , 880-889.		0
453	Excitotoxicity in Huntingtonâ€™s Disease. , 2004, , 243-249.		0
454	New calpain inhibitor preserves brain architecture in 3â€nitropropionic acid (3â€NP) model of Huntington disease. FASEB Journal, 2009, 23, 675.7.	0.2	0
455	Potential Therapies for Mitochondrial Dysfunction. , 2012, , 215-230.		0
456	Mitochondrial Dysfunction, Aging, and Huntingtonâ€™s Disease. , 1994, , 111-126.		0
457	Therapeutic Strategies in Alzheimerâ€™s Disease. , 1997, , 329-336.		0
458	Mitochondrial Dysfunction and Neurodegenerative Diseases. , 1998, , 265-296.		0